New Drug Approved by F.D.A. for Pancreatic Cancer Could Be First of Many
The Food and Drug Administration has approved new treatment options for pancreatic cancer, including the drug daraxonrasib, alongside approvals for breast and lung cancer treatments during the third quarter of 2026. Targeted drugs and personalized vaccines are creating new possibilities for patients beyond standard chemotherapy. Meanwhile, regulatory bodies have issued fresh approvals and breakthrough designations for other oncology indications, such as Tecentriq combined with chemotherapy for stage III dMMR colon cancer and AbbVie's experimental drug Temab-A for advanced colorectal and lung cancers.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The FDA approved daraxonrasib as a new treatment option for pancreatic cancer.
- ✓ The FDA issued approvals for new treatment options covering breast, lung, and pancreatic cancer during the third quarter of 2026.
- ✓ Targeted drugs and personalized vaccines are creating new possibilities for pancreatic cancer treatment beyond chemotherapy.
- ✓ The FDA approved Tecentriq plus chemotherapy for stage III dMMR colon cancer after a trial halved the risk of recurrence or death.
What changed
Recent updates confirm additional regulatory approvals and breakthrough designations for multiple targeted oncology drugs spanning pancreatic, lung, and colon cancers.
Live updates
-
FDA Approves New Targeted Therapies for Cancer
The Food and Drug Administration has approved new treatment options for pancreatic cancer, including the drug daraxonrasib, alongside approvals for breast and lung cancer treatments during the third quarter of 2026. Targeted drugs and personalized vaccines are creating new possibilities for patients beyond standard chemotherapy. Meanwhile, regulatory bodies have issued fresh approvals and breakthrough designations for other oncology indications, such as Tecentriq combined with chemotherapy for stage III dMMR colon cancer and AbbVie's experimental drug Temab-A for advanced colorectal and lung cancers.
Why it matters
Pancreatic cancer remains a difficult disease to treat, historically relying heavily on chemotherapy with limited success. The introduction of targeted therapies and personalized vaccines represents a shift toward more individualized oncology care. Regulatory agencies are accelerating access to these newer modalities through breakthrough designations and swift approvals for various gastrointestinal and pulmonary malignancies.
What is confirmed
- The FDA approved daraxonrasib as a new treatment option for pancreatic cancer.
- The FDA issued approvals for new treatment options covering breast, lung, and pancreatic cancer during the third quarter of 2026.
- Targeted drugs and personalized vaccines are creating new possibilities for pancreatic cancer treatment beyond chemotherapy.
- The FDA approved Tecentriq plus chemotherapy for stage III dMMR colon cancer after a trial halved the risk of recurrence or death.
- The FDA granted AbbVie's experimental cancer drug Temab-A two breakthrough designations for advanced colorectal and lung cancers.
What to watch next
- Further clinical data on the efficacy of daraxonrasib and personalized vaccines for pancreatic cancer.
- Upcoming third-quarter earnings reports and financial updates from pharmaceutical companies like Johnson & Johnson.
confidence 100%Sources used for this update (7)
- jen.jiji.com — Abandoned newborn found in Cinisello, transported to hospital in critical condition
- www.utmb.edu — How new targeted therapies are changing pancreatic cancer ...
- www.nature.com — RevMed’s pancreatic cancer drug first - Nature Biotechnology
- finance.yahoo.com — Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech W....
- nypost.com — Blogger, 41, announces her own death from cancer
- www.medicaldaily.com — AbbVie's Experimental Cancer Drug Temab-A Earns Two FDA Breakthrough Designations for Advanced Colorectal....
- www.medicaldaily.com — Tecentriq Plus Chemotherapy Wins Approval for Stage III dMMR Colon Cancer After Halving Recurrence or Dea....
-
FDA Approves New Drug for Pancreatic Cancer
The FDA has approved a new drug for pancreatic cancer, marking a significant development in the treatment of this disease. The approval brings hope to patients and families affected by pancreatic cancer. The drug, daraxonrasib, is part of a growing trend of new oncology treatments being approved by the FDA. In the third quarter of 2026, the FDA issued approvals for new treatment options for various types of cancer, including breast, lung, and pancreatic cancer.
Why it matters
Pancreatic cancer is a serious disease with a high mortality rate. The approval of new treatments is crucial in addressing this health issue. The FDA's active efforts to approve new oncology treatments reflect the growing need for effective cancer therapies. The Pancreatic Cancer Action Network is a national organization providing support, resources, and hope for people fighting pancreatic cancer.
What is confirmed
- The FDA has approved daraxonrasib for pancreatic cancer.
- In the third quarter of 2026, the FDA issued approvals for new treatment options for cancers of the breast, lung, pancreas, and more.
What to watch next
- Future approvals of new oncology treatments by the FDA
- Clinical trial results for existing cancer treatments
- Updates on the effectiveness of daraxonrasib in treating pancreatic cancer
confidence 80%Sources used for this update (8)
- www.everydayhealth.com — Health News: Latest Research, Top Stories, Trending Topics
- www.cnn.com — Breaking News, Latest News and Videos | CNN
- www.bbc.co.uk — Home - BBC News
- www.nbcnewyork.com — Missouri woman survives colon cancer 3 times, reveals major symptom – NBC New York
- pancan.org — Pancreatic Cancer Action Network – Research, Patient Support, Resources
- jen.jiji.com — Formula 1, today Singapore GP qualifying and sprint race: schedule and where to watch them (free-to-air)
- www.pharmtech.com — Engineered T Cell Receptor-T Cell Therapies | Pharmaceutical Technology
- www.coherentmarketinsights.com — Poly Adenosine Diphosphate-Ribose Polymerase Market Forecast, 2026-2033
-
FDA Approvals in Oncology Continue with New Treatments
The FDA has been actively approving new oncology treatments, including daraxonrasib for pancreatic cancer, and evaluating risks associated with existing drugs like Ibrance, Kisqali, and Verzenio. In the third quarter of 2026, the FDA issued approvals for new treatment options for cancers of the breast, lung, pancreas, and more. These developments aim to address the growing crisis of trust in environmental issues and improve cancer treatment options.
Why it matters
The ongoing climate crisis and growing environmental concerns have led to increased scrutiny of pharmaceutical companies' sustainability efforts. Meanwhile, cancer treatment options are expanding with new FDA approvals, addressing the complexities of the disease and data gaps in decision-making.
What is confirmed
- The FDA approved daraxonrasib in August 2026 for patients with previously treated metastatic pancreatic adenocarcinoma.
- Daraxonrasib is the first approved targeted therapy for pancreatic cancer.
- The FDA is evaluating a possible colitis risk with Ibrance, Kisqali, and Verzenio.
- In the third quarter of 2026, the FDA issued approvals for new treatment options for cancers of the breast, lung, pancreas, and more.
Still unconfirmed
- An overwhelming majority of Italians (62%) are convinced that "there is not a minute to lose" in addressing the climate crisis.
What to watch next
- FDA's final assessment on colitis risk with Ibrance, Kisqali, and Verzenio
- Further data on the effectiveness of daraxonrasib and other new oncology treatments
- Pharmaceutical companies' sustainability efforts and environmental impact assessments
confidence 90%Sources used for this update (4)
- jen.jiji.com — Sustainability: the curtain rises on the CSR Exhibition, three days at Bocconi for a possible future (2)
- www.medicaldaily.com — Colitis Reports with Breast Cancer Drugs Ibrance, Kisqali, and Verzenio Put Them on FDA's Potential Risk ....
- www.medscape.com — ‘Wild West’: Cancer Drug Advances Are Creating Data Gaps
- www.aacr.org — FDA Approvals in Oncology: July-September 2026 | Blog | AACR
-
FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer
The FDA approved daraxonrasib in August 2026 for patients with previously treated metastatic pancreatic adenocarcinoma. Produced by Revolution Medicines, the oral medication is taken once daily and represents the first approved targeted therapy for pancreatic cancer. The drug works by inhibiting RAS proteins, which are primary drivers of the disease. Clinical data indicates that daraxonrasib extends life expectancy and survival for people with advanced stages of the cancer.
Why it matters
Pancreatic cancer is one of the deadliest forms of the disease, and RAS proteins have been historically difficult for scientists to target. This approval follows decades of basic science and public funding. The drug is intended for those who have already undergone previous treatments.
What is confirmed
- The FDA approved daraxonrasib in August 2026 for previously treated metastatic pancreatic adenocarcinoma.
- Daraxonrasib is an oral drug taken once a day.
- The medication is the first approved targeted therapy for pancreatic cancer patients.
- Daraxonrasib inhibits RAS proteins to extend survival for people with advanced pancreatic cancer.
Still unconfirmed
- The drug is referred to as Rasonque by some reports.
- The drug will change cancer treatment forever.
What to watch next
- Publication of RASolute 302 survival data and safety considerations
- Regulatory filing submissions for intismeran autogene in combination with KEYTRUDA
confidence 95%Sources used for this update (22)
- www.fda.gov — Novel Drug Approvals for 2026 | FDA
- www.merck.com — Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoin....
- www.wbaltv.com — FDA panel endorses first-of-a-kind cancer blood test - WBAL
- medcitynews.com — Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder - MedCity News
- immunitybio.com — Latest News in Targeted Cell Therapies for Cancer & Infectious Diseases
- www.sharp.com — New pancreatic cancer drug offers hope - Sharp HealthCare
- www.oncozine.com — Artificial intelligence in Oncology: Where Promise Meets Reality
- cancerexplained.org — A RAS Inhibitor Is Approved for Pancreatic Cancer: Reading ...
- article.wn.com — FDA Approves Drug for Pancreatic Cancer Following ...
- www.onclive.com — Daraxonrasib Approval Signals a New Era for RAS-Targeted ...
- stocktwits.com — AAPL Stock Retreats From All-Time High: Research Firm Says Apple Could Sell 6M iPhone Duos This Year
- gizmodo.com — This Pill Will Change Cancer Treatment Forever - Gizmodo
-
Legend Biotech Reports Five-Year Survival Data for CARVYKTI
Legend Biotech reported a 69.2% five-year overall survival rate for patients with relapsed or refractory multiple myeloma (RRMM) treated with a single infusion of CARVYKTI. Data shows half of these patients remained progression-free and alive after five years. These results provide long-term evidence for the curative potential of the treatment in earlier-line RRMM settings.
Why it matters
This data follows previous reports regarding Takeda's oncology pipeline and upcoming presentations at the European Society for Medical Oncology Congress. Long-term survival rates are critical for evaluating the efficacy of CAR-T cell therapies in treating blood cancers.
What is confirmed
- The five-year overall survival rate for patients treated with CARVYKTI was 69.2%.
- Half of the patients with RRMM remained progression-free and alive five years after a single infusion of CARVYKTI.
What to watch next
- Takeda presentation of Phase 3 data for arcotatug tavatecan at the ESMO Congress from October 23 to 27, 2026.
confidence 100%Sources used for this update (4)
- www.quiverquant.com — Quiver News
- jen.jiji.com — "Russia prepares drone attacks in Spain, France or Italy", El Mundo reveals CIA alert
- jen.jiji.com — Goes to hospital with severe pain and two hours later becomes a mother: the story of Anna Wolfe, who didn't know she was pregnant
- www.marketscreener.com — Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
-
Takeda to Present Late-Stage Oncology Data at ESMO 2026
Takeda will present new oncology pipeline and solid tumor portfolio data at the European Society for Medical Oncology Congress in Madrid from October 23 to 27, 2026. The presentation includes late-breaking Phase 3 data for arcotatug tavatecan (TAK-921) and two presentations regarding TAK-928. These updates focus on the company's late-stage oncology pipeline progress and research into solid tumors.
Why it matters
The ESMO Congress is a major international forum for oncology research. Takeda is collaborating with Innovent R&D on the development of these specific compounds. The data will include both clinical and real-world evidence.
What is confirmed
- Takeda will present oncology pipeline and portfolio data at the European Society for Medical Oncology Congress in Madrid from October 23 to 27, 2026.
- The data will include a late-breaking abstract on arcotatug tavatecan (TAK-921) and two presentations on TAK-928.
What to watch next
- The release of the Phase 3 arcotatug tavatecan data in October
- The presentation of TAK-928 results at the ESMO Congress
confidence 100%Sources used for this update (8)
- jen.jiji.com — Nadal returns to the court: the surprise announcement and the match date - Video
- jen.jiji.com — Cnel, Brunetta mandates lawyers against Conte for "false news" on 'salary' increase
- jen.jiji.com — "Mariotto, you are on 'Ballando' and you don't understand anything about dancing...", Caterina Balivo's jab
- jen.jiji.com — Sarri pokes fun at Juve: "I don't have great memories of that year and no regrets"
- jen.jiji.com — Difficulty sleeping and tiredness upon waking, it's the biological clock's fault: here are 5 rules to reset it
- jen.jiji.com — BC Roma basketball team presents itself at Palatiziano, Mannion: "We want to take the club to the top"
- www.afp.com — Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
- jen.jiji.com — Me Contro Te, site under maintenance after appeal. Consumerism: "Timings match"
-
FBI Alleges Russian Intelligence Targeted Assassinations in US and Europe
Federal authorities in the United States announced the indictment of five individuals allegedly linked to Russian intelligence services plotting targeted assassinations in the US and European countries supporting Ukraine. A Manhattan federal court complaint states that the network paid or attempted to pay operatives to surveil and eliminate targets, alongside planning acts of terrorism against civilian and military infrastructure. James Barnacle Jr., head of the FBI's New York office, stated the agency thwarted the plans. Meanwhile, the Italian government prepared a decree addressing worker protections for former Ilva, and Anthony Scaramucci commented on political figures.
Why it matters
The foiled assassination plot highlights escalating security concerns regarding foreign intelligence operations on domestic soil in nations backing Ukraine. At the same time, labor discussions in Rome highlight ongoing economic pressures within industrial sectors.
What is confirmed
- Russian intelligence services planned targeted assassinations in the United States and European countries supporting Ukraine, according to US federal authorities.
- A Manhattan federal court complaint revealed that an intelligence network paid or attempted to pay individuals to surveil and kill targets.
- James Barnacle Jr., head of the FBI's New York office, stated that the agency thwarted the plans.
Still unconfirmed
- Recruited network members were urged to commit acts of terrorism against civilian and military infrastructure in European countries aligned with Ukraine.
What to watch next
- Arraignment or capture of the five indicted individuals still at large
- Further details from federal authorities on the scope of the targeted assassination network
confidence 90%Sources used for this update (3)
- jen.jiji.com — Ukraine, FBI's warning: "Russia plans targeted assassinations in the US and Europe"
- jen.jiji.com — Former Ilva, government-unions meeting. Mantovano: "We will bring a decree with measures for workers to today's Council of Ministers"
- inews.co.uk — Anthony Scaramucci: Farage is a dumber version of Trump
-
Daraxonrasib Shows Promise in Lung Cancer and Wins FDA Designation
Daraxonrasib, also known as Rasonque, is showing promise in early trials for treating lung cancer in addition to its recent approval for metastatic pancreatic cancer. And the Food and Drug Administration has granted Breakthrough Therapy Designation to daraxonrasib combined with chemotherapy for first-line metastatic pancreatic cancer. Patients dealing with metastatic pancreatic adenocarcinoma have faced insurance hurdles and weeks of waiting to access the daily oral multi-selective RAS(ON) inhibitor following its initial regulatory approval from Revolution Medicines.
Why it matters
The expansion of daraxonrasib into early lung cancer trials and its new breakthrough designation signify broader therapeutic potential for a medication originally targeted at pancreatic tumors. Access remains a critical issue as administrative barriers delay patient treatment despite ongoing regulatory advancements.
What is confirmed
- Daraxonrasib (Rasonque) is showing promise in the treatment of lung cancer in early trials.
- The FDA granted Breakthrough Therapy Designation to daraxonrasib plus chemotherapy in first-line metastatic pancreatic cancer.
What to watch next
- Whether insurance coverage timelines improve for patients prescribed daraxonrasib.
- Further clinical trial results regarding daraxonrasib and treatment-resistant lung cancer.
confidence 100%Sources used for this update (8)
- jen.jiji.com — Lorena Isceri, crowd at the funeral in Squinzano: "Here to take a piece of this family's pain"
- jen.jiji.com — Five thousand dollars for every American? The 'Trump dividends' would cost over a trillion
- jen.jiji.com — Ukraine, bombs on Kyiv: 2 injured. Russian raid on shopping center: death toll rises to 5
- www.medicalnewstoday.com — Pancreatic cancer drug may also help fight treatment-resistant lung cancer
- finance.biggo.com — Andrew Huberman: The MDMA Therapy Setback Wasn't the Drug — It Was the Wild West Around It
- oncodaily.com — FDA Grants Breakthrough Therapy Designation to Daraxonrasib Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer
- jen.jiji.com — Bonino, today State funeral in Rome: Mattarella and Meloni present
- jen.jiji.com — America's Cup, Sport e Salute welcomes a Luna Rossa delegation in Rome
-
Insurance Delays Affect Access to New Pancreatic Cancer Drug Rasonque
Patients are struggling to access Rasonque, a pancreatic cancer drug from Revolution Medicines, despite its FDA approval. While the medication provides a targeted alternative to general chemotherapy, insurance coverage is taking weeks to catch up with the regulatory approval. This gap creates a barrier for adults with metastatic pancreatic adenocarcinoma who require the daily oral multi-selective RAS(ON) inhibitor to treat specific genetic mutations.
Why it matters
The FDA previously approved daraxonrasib to move oncology toward personalized medicine. This shift mirrors the use of mRNA vaccines for melanoma. Current research aims to overcome KRAS resistance to improve long-term patient outcomes.
What is confirmed
- The FDA approved a daily oral multi-selective RAS(ON) inhibitor for adults with metastatic pancreatic adenocarcinoma.
- Rasonque is a pancreatic cancer drug developed by Revolution Medicines.
Still unconfirmed
- Insurance coverage for Rasonque can take weeks to catch up after FDA approval.
What to watch next
- Updates on insurance provider reimbursement policies for Rasonque
- Clinical data on overcoming KRAS resistance to improve long-term effectiveness
confidence 90%Sources used for this update (5)
- www.statnews.com — A breakthrough pancreatic cancer drug won approval. They still struggle to access it
- jen.jiji.com — Raffaella Fico: "I was betrayed, I immediately kicked him out of the house. Let's stop blaming women"
- jen.jiji.com — Early breast cancer: over 30,000 genomic tests prescribed in Italy in 5 years
- jen.jiji.com — Wave of bad weather over Italy: orange and yellow weather alert for thunderstorms on Thursday, September 10
- www.sfexaminer.com — Campaign cash plummets as Supervisor Alan Wong heads for likely full term
-
FDA Approves Daily Pill for Pancreatic Cancer Treatment
The FDA approved daraxonrasib, a daily oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma. This drug targets specific genetic mutations, moving treatment away from general chemotherapy toward personalized oncology. Current medical research now focuses on overcoming KRAS resistance to increase the long-term effectiveness of the treatment. This approval mirrors recent advancements in personalized medicine, such as mRNA cancer vaccines used for melanoma.
Why it matters
Pancreatic adenocarcinoma is traditionally a deadly disease with limited targeted options. The shift toward genetic-specific inhibitors allows doctors to treat the molecular drivers of a tumor. This approach aims to improve patient outcomes by reducing the reliance on broad-spectrum chemotherapy.
What is confirmed
- The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma.
- Daraxonrasib is an oral multi-selective RAS(ON) inhibitor.
- The drug is administered as a daily pill.
What to watch next
- Research data regarding the success of overcoming KRAS resistance
- FDA approval of additional RAS inhibitors for other cancer types
confidence 100%Sources used for this update (5)
- www.dailymail.com — I developed a hidden health problem at 13 that's affecting ever more girls. It left me exhausted, ashamed and struggling with intimacy... we must talk about it before mo…
- www.sfexaminer.com — Tech workers start to see promise in unions
- www.sandiegouniontribune.com — San Diego Union-Tribune
- www.yahoo.com — FDA approves new drug for pancreatic cancer. Who’s eligible and how does it work?
- www.sfexaminer.com — A tidier Rivian (in size and price) is ready for the suburbs
-
FDA-Approved Daraxonrasib Joins Shift Toward Personalized Pancreatic Cancer Care
The FDA has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma. This approval marks a transition toward personalized oncology, mirroring recent progress in mRNA cancer vaccines for melanoma. While daraxonrasib provides a new option for a traditionally deadly disease, current research is now focusing on overcoming KRAS resistance to improve long-term efficacy. These developments indicate a broader trend of targeting specific genetic mutations to treat aggressive cancers rather than relying on generalized chemotherapy.
Why it matters
Pancreatic adenocarcinoma is historically difficult to treat with high mortality rates. The emergence of RAS(ON) inhibitors and mRNA technology represents a move toward precision medicine. Researchers are now investigating how to prevent tumors from developing resistance to these targeted therapies.
What is confirmed
- The FDA approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma.
- Moderna and Merck developed a personalized mRNA cancer vaccine that prevented melanoma recurrence in late-stage trials.
Still unconfirmed
- Susanna Fletcher Greer is researching methods to unlock KRAS resistance.
What to watch next
- Clinical trial results for KRAS resistance inhibitors
- Long-term survival data for patients using daraxonrasib
confidence 90%Sources used for this update (7)
- jen.jiji.com — America's Cup, Frecciarossa official sponsor of Luna Rossa
- jen.jiji.com — US Open, today Musetti-Sweeny - Live
- jen.jiji.com — Kills wife and 14-year-old son then commits suicide in Finale Ligure, alarm raised by employer and the note: what we know
- jen.jiji.com — Vicenzaoro, Peraboni (leg): "We are a point of reference even in a time of crisis"
- www.dailymail.com — Cassandra Thorburn takes a swipe at her ex-husband Karl Stefanovic as she reveals he did not reach out after her cancer diagnosis: 'I know who he is'
- www.dailymail.com — Bella Hadid poses in wet T-shirt and underwear as she lies in river for sizzling new snaps
- oncodaily.com — Susanna Fletcher Greer: Two Hits, One Target – Unlocking KRAS Resistance
-
FDA Approves Daraxonrasib for Pancreatic Cancer
The FDA approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma, marking a shift toward personalized cancer treatments. This development follows a similar breakthrough by Moderna and Merck, whose personalized mRNA cancer vaccine successfully prevented melanoma recurrence in late-stage trials. These advancements offer new options for diseases traditionally considered deadly.
Why it matters
The approval of daraxonrasib and the success of Moderna and Merck's cancer vaccine represent significant progress in the fight against cancer. Pancreatic adenocarcinoma is a particularly challenging disease, and new treatments are urgently needed. The use of targeted inhibitors and vaccines to customize patient care is a promising approach. This trend is expected to continue, with more personalized treatments emerging in the future.
What is confirmed
- The FDA approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma.
- Moderna and Merck's personalized mRNA cancer vaccine successfully prevented melanoma recurrence in late-stage trials.
Still unconfirmed
- Pressure grows among Republicans for Trump to deploy Maga Inc.'s substantial financial resources to support party candidates.
What to watch next
- Further FDA approvals of personalized cancer treatments
- Results from ongoing trials of Moderna and Merck's cancer vaccine
- Development of new targeted inhibitors and vaccines for pancreatic adenocarcinoma
confidence 90%Sources used for this update (5)
- www.fox5dc.com — FOX 5 DC | Local News, Weather, and Live Streams | WTTG
- www.theglobeandmail.com — Globe Investor
- www.nfl.com — NFL NEWS
- jen.jiji.com — Trump hosts at White House Republicans on the fence, pressing on 400 mln
- finance.biggo.com — Moderna CEO Stéphane Bancel: The Algorithm Behind Our Cancer Vaccine Will Only Get Better
-
FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma
The FDA approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma. This approval marks a shift toward personalized cancer treatments that train the immune system to target specific patient cancers. This development follows a similar breakthrough by Moderna and Merck, whose personalized mRNA cancer vaccine successfully prevented melanoma recurrence in late-stage trials. These combined advancements offer new options for diseases traditionally considered deadly by utilizing targeted inhibitors and vaccines to customize patient care.
Why it matters
Pancreatic cancer is traditionally difficult to treat with high mortality rates. The move toward personalized medicine allows for therapies tailored to a patient's specific genetic markers.
What to watch next
- Clinical data on daraxonrasib long-term efficacy
- FDA approval of further personalized mRNA vaccines
confidence 100%Sources used for this update (7)
- omaha.com — HazToGo Fall Mobile Events Offer Free, Convenient Disposal
- journalstar.com — Men turn to cosmetic clinics to complete transformation after GLP-1 weight-loss drugs
- jen.jiji.com — US Open, today Musetti-Fery: schedule, head-to-head and where to watch it on TV
- finance.yahoo.com — MassLive’s Most Influential Innovators of 2026
- jen.jiji.com — USA, Bank of America Vice President is the woman stabbed to death in Times Square
- jen.jiji.com — Inter, Ausilio will not renew contract: leaves club after 28 years
- jen.jiji.com — Rome, fire in a garage on via Vitellia: electric car involved, 6 intoxicated
-
FDA-Approved Pancreatic Cancer Drug Joins New Wave of Personalized Oncology
The FDA has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma. This approval coincides with a broader shift toward personalized cancer treatment, highlighted by a breakthrough from Moderna and Merck. Their personalized mRNA cancer vaccine successfully prevented melanoma recurrence in late-stage trials. Experts describe these developments as the start of an era where vaccines and targeted inhibitors train the immune system to fight a specific patient's cancer, offering new options for diseases traditionally considered deadly.
Why it matters
Pancreatic adenocarcinoma is notoriously difficult to treat and often fatal. The introduction of daraxonrasib provides a new chemical approach to inhibition, while mRNA technology introduces a custom-made immunological approach. Together, these represent a transition from general chemotherapy to patient-specific precision medicine.
What is confirmed
- The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma.
- Moderna and Merck developed a personalized mRNA cancer vaccine that prevents melanoma recurrence in late-stage trials.
What to watch next
- Clinical trial results for mRNA vaccines targeting pancreatic cancer
- Long-term survival data for patients using daraxonrasib
confidence 100%Sources used for this update (9)
- www.straitstimes.com — Success after a century of failures: Inside Moderna and Merck’s cancer vaccine breakthrough
- journalstar.com — Dolly Parton’s immortal music legacy in 10 essential songs
- jen.jiji.com — Germany, knife attack at Rosenheim station: 31-year-old British woman killed
- jen.jiji.com — US Open, Paolini - Erjavec in the first round: live match
- tucson.com — Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough
- journalstar.com — DC’s interstellar peacekeepers have landed in Nebraska — here’s where and why
- jen.jiji.com — Nepal authorities, ‘risk of new floods, at least 800 dead and over 3,000 missing’
- jen.jiji.com — Ranucci Case, Report journalists' assembly: "State of agitation, we will strike if necessary"
- www.applevalleynewsnow.com — Week in review: Test your knowledge of notable news
-
FDA Approves New Drug for Pancreatic Cancer
The US FDA has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma. This approval marks a new approach to treating the disease, which is notoriously deadly. Some patients, including former University of Florida President Sasse, have already received the medication, crediting it with extending their life.
Why it matters
Pancreatic cancer has limited treatment options and poor survival rates. The approval of daraxonrasib offers hope for improved treatment outcomes. This development is part of a larger effort to develop effective treatments for pancreatic cancer.
What is confirmed
- The FDA approved a pill from Revolution Medicines to treat pancreatic cancer.
- The approved drug is designed to improve survival rates for pancreatic cancer.
- Some patients at Dartmouth are among the first to receive the medication.
- Former University of Florida President Sasse credited the drug with extending his life.
- The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.
What to watch next
- Further clinical trials to confirm the efficacy of daraxonrasib
- Development of similar medicines by other pharmaceutical companies
- Long-term effects of daraxonrasib on patients with pancreatic cancer
confidence 90%Sources used for this update (7)
- medicalxpress.com — FDA approval opens new chapter in pancreatic cancer treatment
- jen.jiji.com — Report, Presutti and Piervincenzi to host. Three relocation proposals for Ranucci
- jen.jiji.com — Roller coaster at Six Flags park in California closes: "Linked to brain injuries, coma, and deaths"
- journalrecord.com — After a century of failures, cancer vaccine hits major milestone
- jen.jiji.com — Ukraine, Russian raid against warehouse near Kyiv causes massacre: at least 27 dead
- www.news-medical.net — FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber
- jen.jiji.com — Return migration, Codacons: "Chaos between construction sites and expensive fuel, odyssey for motorists"
-
FDA Approves First-of-a-Kind Pancreatic Cancer Pill from Revolution Medicines
The Food and Drug Administration approved a first-of-a-kind pill from Revolution Medicines on Wednesday to treat pancreatic cancer. The drug is designed to improve survival rates for a disease noted for being notoriously deadly. Some patients at Dartmouth are among the first to receive the medication. Former University of Florida President Sasse credited the drug with extending his life. This approval marks a new approach to treating the disease and has sparked a race to develop similar medicines.
Why it matters
Pancreatic cancer is traditionally difficult to treat with high mortality rates. This approval introduces a new class of medication that experts believe will transform standard care. The development positions Revolution Medicines as a potential major player in oncology.
What is confirmed
- The FDA approved a new drug for pancreatic cancer on Wednesday.
- Revolution Medicines developed the first-of-a-kind pill for the disease.
- The drug is intended to improve survival for patients with pancreatic cancer.
Still unconfirmed
- The drug is named Rasonque.
- Revolution Medicines could become the next oncology titan.
What to watch next
- FDA approval of subsequent medicines following this new treatment model.
confidence 90%Sources used for this update (10)
- WSJ — FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease
- The New York Times — F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer
- The New York Times — The Race to Develop More Medicines Like the New Pancreatic Cancer Drug
- WMUR — Dartmouth patients among first to get new drug that fights pancreatic cancer
- www.forbes.com — Forbes Daily: Nvidia Beats Expectations As Data Center Business Grows
- BioSpace — RevMed could become ‘next oncology titan’ with Rasonque nod
- www.today.com — FDA Approves ‘Game-Changing’ Pancreatic Cancer Drug
- www.statnews.com — Decoding DEA action on kratom-related substances
- www.usatoday.com — FDA approves pancreatic cancer drug Sasse credits with extending his life
- www.kpbs.org — FDA approves landmark pancreatic cancer drug that's shown to improve survival
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community